Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTreatment OutcomeTransplantation ChimeraStem CellsGraft vs Leukemia EffectBone Marrow TransplantationMyeloablative AgonistsTissue DonorsBusulfanRemission InductionRecurrenceVidarabineGraft vs Tumor EffectGraft SurvivalSurvival RateHistocompatibility TestingRetrospective StudiesDisease-Free SurvivalLymphocyte TransfusionSurvival AnalysisImmunosuppressive AgentsLeukemia, Myeloid, AcuteMultiple MyelomaCombined Modality TherapyLeukemiaSiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCord Blood Stem Cell TransplantationCytomegalovirus InfectionsHematopoietic Stem CellsSalvage TherapyMinor Histocompatibility AntigensLiver TransplantationWhole-Body IrradiationLymphocyte DepletionMyelodysplastic SyndromesAntilymphocyte SerumNeoplasm, ResidualVirus ActivationTime FactorsPrecursor Cell Lymphoblastic Leukemia-LymphomaHistocompatibilityMelphalanChimerismAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesHepatic Veno-Occlusive DiseaseCyclophosphamideMesenchymal Stem Cell TransplantationPrognosisCytomegalovirusHematopoietic Stem Cell MobilizationT-LymphocytesAcute DiseaseKidney TransplantationPrimary MyelofibrosisCell TransplantationAnemia, AplasticHLA AntigensEmbryonic Stem CellsHematologic DiseasesLeukemia, Myeloid, Accelerated PhaseAntigens, CD34Antineoplastic AgentsAntibodies, NeoplasmCytarabineImmunosuppressionTransplantation ImmunologyBenzamidesRoseolovirus InfectionsAdult Stem CellsLeukemia, MyeloidImmunocompromised HostLymphoproliferative DisordersFusion Proteins, bcr-ablHodgkin DiseasePyrimidinesGraft RejectionCell SurvivalReceptors, Purinergic P2X5Prospective StudiesNuclear FamilyLymphoma, Non-HodgkinRisk FactorsPiperazinesInfectionFatal OutcomeGanciclovirGranulocyte Colony-Stimulating FactorHeart TransplantationCyclosporineImmunotherapy, AdoptiveCell Differentiation